What Justice Ginsburg’s Death Means For Pharma
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
You may also be interested in...
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.
GlaxoSmithKline win shows value of going to court as US FDA is less likely to take action against comparative promotions. Court was swayed by GSK survey showing likely harm caused by ‘false and misleading statements not supported by scientific studies.’
The US pharmaceutical industry has to be pleased with the tone set by the Democratic National Convention that formally nominated Joe Biden for President. The campaign looks to be about Trump, COVID, and healing racial divisions, not drug prices.